You need to download the latest flash player - download it here

  • About Us
    • Management Team
    • Board of Directors
    • Personalized Medicine
  • Development
    • OMAPRO™ (omacetaxine mepesuccinate)
    • Quinamed® (amonafide dihydrochloride)
  • Investors
    • Financial Reports
    • Presentations
    • Corporate Governance
    • Analyst Coverage
    • Information Requests
  • News, Media & Events
    • Recent Press Releases
    • Press Release Archive
    • Media Contact
  • Clinical Trials
    • Chronic Myelogenous Leukemia
    • Myelodysplastic Syndrome
    • Solid Cancers
  • Careers
    • Culture
    • Current Openings
  • Recent Press Releases
  • Press Release Archive
  • Media Contact

Recent Press Releases


July 14th, 2010

ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO™

June 7th, 2010

ChemGenex Announces Positive Safety Data on OMAPRO™ Presented at ASCO

May 4th, 2010

ChemGenex to Host Investor Briefing

April 12th, 2010

ChemGenex Receives A Complete Response Letter From The FDA For OMAPRO™

March 23rd, 2010

U.S. Food and Drugs Administration’s Oncologic Drug Advisory Committee Recommends ChemGenex Validate a Diagnostic Prior to Approval of OMAPRO™ in Chronic Myeloid Leukemia Patients with T315I Mutation

March 2nd, 2010

U.S. Food and Drug Administration (FDA) Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review OMAPRO™

February 9th, 2010

Extreme Weather in Washington D.C. has Postponed the FDA’s Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010

December 17th, 2009

ChemGenex Pharmaceuticals Announces Omapro™ to be Reviewed by the FDA’s Oncologic Drugs Advisory Committee

December 14th, 2009

ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe

December 9th, 2009

Omapro™ Featured During ASH Oral Session

Home Contact Us Sitemap

© 2010 ChemGenex Pharmaceuticals

Terms of Use